Intraocular inflammation resisting implant as well as preparation method and application thereof

An implant and endophthalmitis technology are applied in the field of implants for the treatment of intraocular inflammation and their preparation to achieve the effects of controlling inflammatory symptoms and reducing systemic drug toxicity

Active Publication Date: 2016-11-09
何伟 +2
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in clinical application, in addition to the continuous administration of drugs, a large drug concentration is required to control the inflammatory response in the early stage of drug use, and the traditional drug sustained release system cannot meet the demand

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intraocular inflammation resisting implant as well as preparation method and application thereof
  • Intraocular inflammation resisting implant as well as preparation method and application thereof
  • Intraocular inflammation resisting implant as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] (1) Preparation method

[0023] Under the protection of high-purity nitrogen, 1.0g of chlorogenic acid and 9.0g of lactide-co-glycolide (weight average molecular weight: 100,000) were mixed evenly, in a miniature twin-cone twin-screw extruder, at 180°C , co-melt-extruded columnar body, as the "core".

[0024] 2.0g lactide-glycolide copolymer (lactide accounts for 50% by mole percent, intrinsic viscosity is 0.7) and 0.04g chlorogenic acid are dissolved in 20mL " chloroform-acetone " mixed solvent (V 氯仿 :V 丙酮 =2:1), the prepared mixed solution is passed through an electrospinning machine, and a layer of electrospinning film loaded with chlorogenic acid is wrapped around the columnar body as a "shell". The process parameters of electrospinning were: voltage 30kV; injection rate: 2.0mL / h; distance between nozzle and receiving plate: 150mm; electrospinning time: 10h, and the implant was prepared.

[0025] The prepared implant was cooled and then cut to obtain a cylindrica...

Embodiment 2

[0034] Under the protection of high-purity nitrogen, mix 0.1g of chlorogenic acid and 9.9g of polyglycolide (weight average molecular weight: 10,000) evenly, in a miniature twin-cone twin-screw extruder (SJZS-7AY), at the extrusion temperature At 130°C, they were co-melted and extruded to form a columnar body as a "core".

[0035]Dissolve 2g of polylactide and 0.08g of chlorogenic acid in 20mL of "chloroform-acetone" mixed solvent (V 氯仿 :V 丙酮 =2:1)), the prepared mixed solution is passed through an electrospinning machine, and a layer of electrospinning film loaded with chlorogenic acid is wrapped around the columnar body as a "shell". The process parameters of electrospinning were: voltage 30kV; injection rate: 2.0mL / h; distance between nozzle and receiving plate: 300mm; electrospinning time: 15h, and the implant was prepared.

[0036] The prepared implant was cooled and then cut to obtain a cylindrical shape with a diameter of 2.0 mm and a length of 5.0 mm to obtain an ant...

Embodiment 3

[0038] Under the protection of high-purity nitrogen, 0.5g chlorogenic acid, 4.5g polylactide (weight-average molecular weight: 5,0000), and 5.0g poly-dioxanone (weight-average molecular weight: 50,000) were mixed evenly, and In a micro-twin-cone twin-screw extruder (SJZS-7AY), at an extrusion temperature of 150°C, they are co-melted and extruded to form a columnar body as a "nucleus".

[0039] Dissolve 2g polyglycolide and 0.10g chlorogenic acid in 20mL "chloroform-acetone" mixed solvent (V 氯仿 :V 丙酮 =1:1), the prepared mixed solution was passed through an electrospinning machine, and a layer of electrospinning film loaded with chlorogenic acid was wrapped around the columnar body as a "shell". The process parameters are: voltage 30kV; injection rate: 2.0mL / h; distance between the nozzle and the receiving plate: 200mm; electrospinning time: 8h, and the membrane is obtained.

[0040] The prepared implant was cooled and then cut to obtain a diameter of 2.0 mm and a length of 5....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
lengthaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to an intraocular inflammation resisting implant as well as a preparation method and application thereof. The intraocular inflammation resisting implant has a core-shell structure; a core layer is a cylindrical object formed by coextrusion by using a melt extrusion method after chlorogenic acid serving as an effective component and a drug carrier are mixed; a shell layer is a layer of electrostatic spinning membrane loading the chlorogenic acid wrapping the outer surface of the cylindrical object by using an electrospinning method after the chlorogenic acid serving as the effective component and the drug carrier are mixed. Compared with a traditional systematic administration mode, the intraocular inflammation resisting implant disclosed by the invention has the advantages that the systematic drug toxicity can be greatly reduced while the concentration of a local effective drug is guaranteed; importantly, the intraocular inflammation resisting implant disclosed by the invention has the core-shell structure, wherein the shell layer is an electrostatic spinning layer, and the release speed of the drug is faster; the core layer is a melt extrusion layer, and continuous release of the drug can be realized.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to an implant for treating intraocular inflammation and a preparation method thereof. Background technique [0002] Effective intraocular drug concentration is the key to the treatment of eye diseases. However, due to the existence of the "blood-eye" barrier, traditional administration methods such as oral administration, topical eye drops, and peribulbar injection often cannot meet clinical needs. Although intravitreal injection is more efficient, it is prone to complications such as intraocular hemorrhage and retinal detachment. Therefore, the development of a safe and effective drug delivery method has broad prospects for clinical application. [0003] In recent years, research on intraocular sustained-release drug delivery systems has made great progress. The intraocular sustained-release drug delivery system can better overcome the weaknesses of traditional drug delive...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K47/34A61K31/216A61P27/02A61P29/00D01D5/00
CPCA61K9/0002A61K9/0051A61K9/0092A61K31/216A61K47/34D01D5/0015D01D5/0084
Inventor 王连嵩何伟
Owner 何伟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap